Prof Robin Foa talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about targeted treatments that are an alternative to HSCT in Ph-positive ALL.

Prof Foa outlines that we have learned that we are able treat to chronic myeloid leukaemia and Philadelphia-like ALL with tyrosine kinase inhibitors.

He understands that the evidence lacks a large randomised study, as it is a sub group of a rare disease.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.